Tokyo, Japan

Shin-ichi Kitamura

This inventor holds 3 USPTO granted patents. Top assignees: Eisai Company, Limited, Jeol Ltd.. Active years: 1977-2026.


% Patents Active = 66.7

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 32(Granted Patents)


Company Filing History:


Years Active: 1977-2026

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Shin-ichi Kitamura

Introduction

Shin-ichi Kitamura is a noteworthy inventor based in Tokyo, Japan, recognized for his innovative contributions in the field of pharmacology. With a total of two patents, his work primarily focuses on compounds that exhibit significant biological activities.

Latest Patents

Kitamura's latest patents include the development of Bis-(meta-amidinophenoxy)-compounds and their pharmacologically acceptable acid addition salts. These compounds demonstrate excellent antifungal, antibacterial, and anti-trichomonal activities, showcasing his commitment to improving healthcare through scientific innovation.

Career Highlights

Shin-ichi Kitamura is currently associated with the Eisai Company, Limited, a reputable organization in the pharmaceutical industry. His role at Eisai highlights his dedication to advancing medical solutions, particularly those aimed at combating infections and microbial resistance.

Collaborations

Throughout his career, Kitamura has collaborated with notable colleagues, including Sachiyuki Hamano and Tamotsu Kanazawa. These partnerships have likely contributed to the success of his innovative work, emphasizing the importance of teamwork in research and development.

Conclusion

Shin-ichi Kitamura's contributions to the field of pharmacology through his patents reflect his innovative spirit and commitment to advancing medical science. His work not only enhances our understanding of pharmacologically active compounds but also paves the way for future advancements in medicine.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…